Beta Bionics, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
BBNX$16.52-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
(In thousands, except number of shares)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $30,432 | $26,566 |
| Short-term investments | 73,143 | 70,179 |
| Accounts receivable, net | 11,996 | 4,448 |
| Inventories, net | 13,320 | 1,245 |
| Prepaid expenses and other current assets | 4,032 | 1,183 |
| Total current assets | 132,923 | 103,621 |
| Property and equipment, net | 4,776 | 2,476 |
| Operating lease right-of-use asset | 6,645 | 3,722 |
| Restricted cash | 100 | 100 |
| Deferred offering costs | 5,051 | — |
| Other long-term assets | 150 | 121 |
| Total assets | $149,645 | $110,040 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $2,852 | $1,166 |
| Accrued expenses and other current liabilities | 15,828 | 8,128 |
| Operating lease liabilities | 1,529 | 1,224 |
| Deferred revenue | 939 | 87 |
| Total current liabilities | 21,148 | 10,605 |
| Operating lease liabilities, net of current portion | 5,726 | 2,999 |
| Deferred revenue, net of current portion | 1,860 | 255 |
| Warrant liabilities | 44,898 | 37,573 |
| Total liabilities | 73,632 | 51,432 |
| Commitments and contingencies (Note 18) | ||
| Convertible preferred stock (Series A, A-2, B, B-2, C, D and E), par value of $0.0001 per share; 34,966,547 and 26,434,390 shares authorized at December 31, 2024 and 2023, respectively; 17,228,954 and 12,876,561 shares issued and outstanding at December 31, 2024 and 2023, respectively; liquidation preference of $355,162 and $295,162 at December 31, 2024 and 2023, respectively | 321,373 | 261,713 |
| Stockholders’ deficit: | ||
| Class A common stock, par value of $0.0001 per share; 5,790,000 and 6,000,000 shares authorized at December 31, 2024 and 2023, respectively; 2,939,085 and 2,989,847 shares issued and outstanding at December 31, 2024 and 2023, respectively | 1 | 1 |
| Class B common stock, par value of $0.0001 per share; 70,000,000 and 65,000,000 shares authorized at December 31, 2024 and 2023, respectively; 3,679,790 shares and 2,982,562 issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Class C common stock, par value of $0.0001 per share; 96,910 and 100,000 shares authorized at December 31, 2024 and 2023, respectively; 48,918 shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Additional paid-in capital | 51,311 | 26,421 |
| Accumulated other comprehensive income | 65 | 137 |
| Accumulated deficit | (296,737) | (229,664) |
| Total stockholders’ deficit | (245,360) | (203,105) |
| Total liabilities, convertible preferred stock and stockholders’ deficit | $149,645 | $110,040 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.